Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 6;73(11):e4020-e4024.
doi: 10.1093/cid/ciaa1637.

Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)

Jakob Malsy  1 , Luzia Veletzky  1 , Janna Heide  1   2 , Annette Hennigs  1 , Ines Gil-Ibanez  1 , Alexander Stein  3   4 , Marc Lütgehetmann  2   5 , Ulrich Rosien  6 , Dorothea Jasper  6 , Sven Peine  7 , Jens Hiller  7 , Friedrich Haag  8 , Stefan Schmiedel  1 , Samuel Huber  1 , Sabine Jordan  1 , Marylyn M Addo  1   2 , Julian Schulze Zur Wiesch  1   2
Affiliations

Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)

Jakob Malsy et al. Clin Infect Dis. .

Abstract

We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

Keywords: COVID-19; convalescent plasma; follicular lymphoma; obinutuzumab; remdesivir.

PubMed Disclaimer

Publication types

LinkOut - more resources